Brief: Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial

Pliant Therapeutics

15/07/2024 13:06

July 15 (Reuters) - Pliant Therapeutics Inc  PLRX.O :
    * PLIANT THERAPEUTICS ANNOUNCES POSITIVE LONG-TERM DATA FROM
THE
INTEGRIS-PSC PHASE 2A TRIAL DEMONSTRATING BEXOTEGRAST WAS WELL
TOLERATED AT 320 MG WITH CONTINUED ANTIFIBROTIC AND
ANTI-CHOLESTATIC ACTIVITY DISPLAYED ACROSS MULTIPLE MEASURES
    * PLIANT THERAPEUTICS- BEXOTEGRAST AT 320 MG WAS WELL
TOLERATED UP
TO 40 WEEKS OF TREATMENT WITH NO TREATMENT-RELATED SEVERE OR
SERIOUS ADVERSE EVENTS
    * PLIANT THERAPEUTICS INC - CONTINUED IMPROVEMENT IN
HEPATOCYTE
FUNCTION AND BILE FLOW BY CONTRAST MRI IMAGING OBSERVED FROM
WEEK 12 TO WEEK 24
    * PLIANT THERAPEUTICS INC - 320 MG COHORT DEMONSTRATED
IMPROVEMENT
IN LIVER STIFFNESS BY TRANSIENT ELASTOGRAPHY AT WEEK 24 COMPARED
TO PLACEBO
    * PLIANT THERAPEUTICS INC - STATISTICALLY SIGNIFICANT
IMPROVEMENT
IN ALKALINE PHOSPHATASE (ALP) LEVELS OVER 24 WEEKS COMPARED TO
PLACEBO

Source text for Eikon:  ID:nGNX86bDXY 
Further company coverage:  PLRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))